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Introduction
Hormonal pregnancy tests have been used for the early diagnosis of
pregnancy or amenorrhea of short duration since the late 1940's. They are
considered simple, inexpensive, accurate and, until recently, safe diagnostic
agents that could be given up to several weeks into pregnancy. They contain
naturally occurring or synthetic progesterones with estrogens. Their mechanism
of action is based on progesterone induced withdrawal bleeding in the estrogen
primed (proliferative phase) endometrium. That is, orally or parentally
administered progesterone v/ith estrogen is given over a two to three day
period then abruptly discontinued. If the woman is not pregnant the pro-
gesterone stimulated endometrium will be sloughed ~nd bleeding induced. How-
ever, if she ;s pregnant the endometrium will be ~3intained by progesterone
output from her own corpus luteum and/or the developing placenta.
Hormonal pregnancy tests were initially developed from progesterone
and estrogen compounds used in the treatment of primary amenorrhea. l Their
composition and usage was refined by numerous physicians into the oral and
injectable pregnancy tests of today.2-7 Most hormonal pregnancy tests are
composed of from 2.5mg to lOmg norethisterone acetate or 50mg ethisterone
(progesterones) with from .02 to .05mg ethinyl estradiol (estrogens). Numer-
ous companies around the world have produced and ~arketed them under various
names: U.S.A. -- Squibb "Gestest" and Roussel "Pro-Duosterone"; Canada -- Will
"Duphaston", Barlowe and Cote IIEstro-Prodial ll and "Ethisterone"; West Germany
•
Schering A.G. and Knoll A.G. "Primodos oral II and J!Duogynon simplex"; Jordan
and U.A.R. -- Schering A.G. "Duogynon" and "Prirr:odos forte ll • 8- 13•
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The teratogenic potential of any drug administered during pregnancy
has generally been thoroughly investigated by the ~2nufacturer and the F.D.A.
Because of the use of hormonal pregnancy tests since the 1940·s, there had
been' much clinical evidence of their efficacy with no reports of associated
congenital malformation. Thus, hormonal pregnancy tests were considered safe
to the embryo with only the adverse effects on the user being investigated.
In 1961, the F.D.A. examined the clinical literature and passed hormonal
pregnancy tests as safe and effective for their intended purpose. However,
since 1962 there has been mounting controversy regarding the teratogenic
potential of hormonal pregnancy tests. Some researchers have found no terato-
genic connection while others have implicated thex in masculinization of the
female fetus, congenital neural tube defects (meningomyelocele and hydrocephalus),
congenital heart and VACTEL malformations, spontan~ous abortions, still births,
and congenital limb bud defects.
Review of the Literature
.
In 1962 Dubowitz14 reported masculinization (non-adrenal female pseudo-
hermaphordism) of a female infant whose mother had used hormonal pregnancy
tests. Masculinization of the female fetus had long been known as an adverse
. 15-17
side effect of progesterone therapy for spontaneous abortlon. However, this
was the first time a hormonal pregnancy test had been mentioned as a possible
cause. Then in 1967, Gal et al 18- 20 did a retrospective study of the mothers
of 100 babies born with spina bifida and hydrocephalus and compared them to
100 matched controls who bad delivered healthy bab~es. There was a signif-
icant difference in the number of hormonal pregnancy tests used by the
affected group as compared to the controls. Thus, there vias a possible
.
association between congenital neural tube defects end hormonal pregnancy
tests. Mitchell et al ,21-22 . in a study of heart disease in 56,109
- 3 -
birth suggested a possible correlationvtith hormonal therapy during
pregnancy and congenital transposition of great vessels (T.G.V.) of the
heart. Nora and Nora23 in a study of 10 patients with the congenital
anomaly kno\'/n by the acronym VI'"\CTEL (vetebral, anal, cardi ac, tracheal,
esophageal, limb defects) found 8 had been exposed to hormonal pregnancy
tests. Also, a retrospec~ive study of 224 children born with con-
genital heart disease found that a significant number had received pro-
gesterone \A,i th estrogen duri ng the cri ti cal peri ad of cardi ogenesi s,
resulting in heart malformations, primarily transposition of the great
vessels. In addition Levey et al~2 did a retrospective study of 76 cases
born \'-lith T.G.V. and concluded that hornlonal pregnancy tests or sex
hormones during pregnancy could be a predisposing factor in congenital
T.G.V. Nost recently, Janerick et al. 24 found that women \'Jho had
used oral contraceptives during pregnancy, hormonal supportive therapy,
or hormonal pregnancy tests had a higher' number of offspring \~Jith con-
.
genital limb bud defects when compared to matched control mothers. Lastly,
exogenous hormones have been implicated in increased spontaneous abortion
rate and increased still bi rth numbers. Brotherton and Craft25 found
that out of 91 spontaneous abortions 7.6% had taken hornlonal pregnancy
tests. The Royal College of General Practitioners· survey on the outcome
of pregnancy found a 10% abortion rate after "primodos ll administration. 20
Crombie et al~6 found a significant excess of hormone prescriptions in
a survey of still births. Thus, retrospective studies have implicated
hormonal pregnancy tests as possible teratogens.
In contrast several researchers have found conflicting evidence to the
previous works. Dubm·titz and Srnithells27 studied 189 mothers who had
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used hormonal pregnancy tests and found that none of the female offspring
suffered from masculinization. Laurence et al 28 in a study similar
to Gal's, compared 271 mothers of spina bifida children to 323 matched controls
and found no significant as~ociat!on between hormonal pregnancy tests and
children with neural tube defects. In 1973 Oakley and Flynt29 did a retrospec-
tive study of Atlanta women who gave birth to malformed children. Out of 433
women, 46 had taken hormonal pregnancy tests during the first trimester.
The proportion of women with positive histories of hormonal pregnancy tests
in each malformed group did not differ significantly from the proportion
observed in the total. However, he concluded that there was an unusually
large number with esophageal atresia and that studies other than retrospective
ones could give more convincing evidence. Lastly, in response to the findings
of Nora and Nora, David and O·Callaghan 30 tested the hypothesis that
hormonal pregnancy tests may cause esophageal atresia as part of VACTEL
syndrome. They compared the sale of hormonal pregnancy tests and occurrence
of esophageal atresia over a 30 year pel~iod in South West England; but they
found no linear trend to indicate an association. Thus, there has been con-
flicting research on hormonal pregnancy tests as teratogens.
Statement of Purpose
In 1973 the F.D.A. reviewed the clinical evidence since 1961 and the
National Academy of Science - National Research Council D~Jg Efficacy's
report and made the recommendation to withdra\1 approval of hormonal pregnancy
31
tests. Thus, the F.D.A. reported in the Federal Register (1973) that
"Gestest" made by Squibb and other similar preparations CGuld be potentially
dangerous during pregnancy, and that proof of the drug's safety. was lacking.
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In response to the reconlmendation) Squibb removed "Gestest" from their
products even though IIGestes t II \'/as 1is ted in the 1974 P.O. R. 32 However,
the final ruling had not been issued by the F.D.A. and legally hormonal
pregnancy tests could be produced and marketed in the U.S. 33 In 1975
Roussel, makers of "Pro-Duosterone ll , ~/ere still sell ing their product; and
did not plan on removing it from the market. 34 Then in March 1975, the
F.D.A. made their final ruling and all hormonal pregnancy tests were dis-
continued in the U.S. 36
Of particular interest is that the initial F.D.A. approval in 1961
and the recommendation to withdrawal approval were based entirely on
clinical evidence supplied by the manufacturers and found in the literature
quoted. As far as could be determined no animal studies had been used in
the evaluation of the product. For example) previous to March 1975, the
medical director and vice-president of Roussel felt that the clinical
evidence was sufficient proof of safety, and that animal studies were
unnecessary.34 Squibb reported that "Gestest ll had been evaluated on only
clinical evidence. 32 Also, the F.D.A. stated that they had neither con-
ducted nor authorized any animal experimentation on the teratogenic potential
33
of this recently controversial drug.
The purpose of this study was to investigate the teratogenic potential
of oral hormonal pregnancy tests on pregnant Sprague Dawley rats. The drug
was administered in both physiological and potentially teratogenic dosages
to the animals. The mothers were sacrificed and the fetuses were examined
for various congenital anomalies.
Material and Methods
Animals: Thirty-eight female Sprague-Dawley 21bino rats of 200-250
gram weights were divided into two groups. T~e control group consisted
of fifteen rats and the experimental group cc~sis~ed of twenty-three rats.
The control group was further divided into three subgroups of five animals
each and the experimental group into four sub;ro~~s of five animals each
and one subgroup of three animals. The females were purchased as timed
pregnant rats from Charles Rivers Laboratories, Xassachusetts. The rats
had been paired with male animals for fertilization from 5 P.M. to 8 A.M.
Pregnancy was indicated by a vaginal smear the follc'",ing morning, and a
positive smear was recorded as day zero of pregn~ncy.37 On the seventh
day of pregnancy the animals were shipped by tru:k to the University of
Connecticut Health Center. Throughout the experi~ental period water and
a commercial diet were allowed ad libitum to all tbe animals.
Medication: Pro-Duosterone·with the f01~~~la (ethisterone - 50.00mg
and ethinyl estradiol - O.03mg) was used as the ~odel hormonal pregnancy
test in this experiment. The ethisterone and ethinyl estradiol were
obtained as pure hormones from the Sigma Chemical Co~pany.38 Using pure
hormones instead of prepared Pro-Duosterone eli~inated any possibility
Qf not being able to obtain the drug should it be removed from the market.
The b~sic animal dosages of ethisterone (204 ~g) and ethinyl estradiol
(0.122 ~g) were calculated for a 225 gram rat at a level proportional by
weight to that consumed by a reference woman at 55 Kg. The appropriate
dosages v/ere weighed on a Sartorius electronic balance type 2472.' The
drug (ethisterone and ethinyl estradiol) was suspended in a solution of
•
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normal saline with 0.4% polysorbate 80. The polysorbate 80 ~las added to
assure a uniform suspension, as ethisterone and ethinyl estradiol were not
water soluble and could possibly precipitate out before the appropriate
39dosage was drawn off. In addition) the hormones were passed through a
forty-four micron pharmaceutical seive prior to vleighing and suspension.
Reduction in particle size greatly reduced precipitation time once in
solution. The hormone and saline mixture was prepared fresh at the be-
ginning of each three day administration period and kept refrigerated
at 38 F. to prevent any loss of potency or degradation of the drug. 40
The 5 experimental groups and 3 control groups received the following
dosages:
Group I, controls - nothing
Group II, controls - 0025 ml normal saline
-Group III, controls -
Group IV,
Group V,
Group VI,
.025 ml normal saline. 0.4% polysorbate 80
solation
basic dosage (204 ~g ethisterone and .122 ~g
ethinyl estradiol) in .025 ml normal saline
0.4% polysorbate 80 solution.
one-half the basic dosage (102 ~g ethisterone
and e06l ~g ethinyl estradiol) in .025 ml normal
saline 0.4% polysorbate 80 solution.
two times the basic dosage (408 ~g ethisterone
and .244 ~g ethinyl estradiol) in .025 ml normal
saline 0.4% polysorbate 80 solution. •
Group VII,
Group VIII,
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five times the basic dosage (1020 ~g ethisteron~
and .610 ~g ethinyl estradiol) in .025 ml normal
saline 0.4% polysorb~te 30 solution.
twenty times the bcsic cQsage (4080 ~g
ethisterone and 1.240 ~s ethinyl estradiol) in
.025 ml normal sali~e O.4~ polysorbate 80 solution.
Timing of Administration: Each animal received .025 ml of suspension by
stomach tube three times per day at four hour intervals (9 A.r~. - 1 P.M. -
5 P. M.) on the 11 th, 12th, and 13th day of pregnancy. The fi rst t\aJO doses
(9 A.M. and 1 P.~1.) \vere at the standard dosages, ho\".~ever, the third dose
(5 P.M.) was at double the concentration of hormones in .025 ml. The double
concentration was necessary to duplicate the hUQan ac~inistration pattern
of four times per day. The three day regimen also duplicated the human
treatment pattern of three consecutive days.41 Th~ 11th, 12th, and 13th
days were selected because they eovered the organoge~ic period in the rat
that would include most of the human anomalies repor~ed in the literature
following hormonal pregnancy tests. Thus, the d~~Uj Vias given during the
rat's critical period for the anomalies being investigated in this study.42-45
The 13th day in the rat is the critical period in development of the appendages
(digits and limbs), vertebra, skull, the ribs and the secondary palate.
The 12th and 13th days are ~lhen final sexual differentiation occurs and anal
and genital anomalies can occur. The three day period would also be critical
for development of the sense organs, fusion of facial processes, and spinal
anomalies (spina bifida, etc.) if they are to occur in the rat. The earlie~
11th day is important for development of the tail and esophagus.
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Data Collected: On the 19th day of pregnancy the animals were
sacrificed by ether anesthesia, the fetuses removed, and the following
data collected:
1. Number of alive, dead, and resorbed fetuses in each group
2. Weight and crown-rump length of each live fetus
3. Sex of each live fetus.
The incidence of the following anomalies was recorded:
1. Cleft lip
2. Cleft palate
3. Cleft lip and palate
4. Facial clefts
5. Anencephaly
6. Exencephalus
7. Hydrocephalus
8. Spina-bifida (meningocele)
9. Spina-bifida (n~elomeningocele)
10. Spina-bifida (nlyeloschisis)
11. Anopthalmia
12. Microphthalmia
13. External ear position and anomalies
14. Anal and genital anomalies
15. Hypoplastic tail
16. Joined twins
17. Limb and paw defects
In addition, fetuses were stained with alizarin red according to
46
the Humason method to allow examination of the skeletal system for
anomalies of:
1. Ri bs
2. Vertebra
3. Limbs
4. Digits
5. Skull
Weight, Crown-rump length, and Sex determination: Before weighing,
fetuses were blotted dry to remove excess fluids and blood. They were
then weighted on a Sartorius electronic scale type 1106. Crovln-rump length
-,u-
was measured along the dorsal surface v/ith a flexible millimeter ruler
from the tip of the nose to the base of the tail. Sex was determined by
42
the nlethod descri bed by Rugh. Cro\'/n-runlp measurements and sex \~ere
determined by one investigator.
Skeletal examination: All skeletal ele~ents were examined under a
dissecting microscope at approximately 7X by a single observer. The
number of vertebrae and ribs vIas recorded; and the skeleton examined for
rudimentary and malformed ribs, limbs) digits, skull and facial bones.
RESULTS
For each treatment group.the following variables were determined:
1. Mean nunlber of implantation sites
.2. Mean number of live fetuses
3. Percent of resorbed fetuses
4. Percent of fetuses that were male
5. Mean total fetal weight of each group (fig. 1)
6. Mean individual fetal weight
7. Mean individual fetal length.
One-way analysis of variance \yas performed for variables one to five
described above. Statistical analysis found no significant diffel~ence at
the .05 level for these variables (fig. 2). No discernible difference
between groups for variables six and seven were observed (fig. 3).
All fetuses were examined for the external ~alformations listed in the'
material and methods. Infrequent minor anomalies ~:ere detected in both
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control and experimental groups; however, there was no tendency for an
increased frequency in the groups receiving the hormones. No major external
anomalies such as: cleft palate, spina-bifida, hydrocephalus, etc. were ,
found in any fetuses (fig. 13,14,15). Only one fetus 'in the group receiving
2X of. the bas i c dose had a defofmed 1eg (fi g. 4).
Minor anonlalies found included: extended tail tips, dark spots on
the medial dorsal surface, and one to t~/o enlarged digits. Extended tail
tips were defined as an extra soft tissue tip greater than lmm on the end
of the tail (fig. 5). Numerous fetuses in all groups had extended tail tips
less than 1 mm; however, only two fetuses iri the 5X group had extended tail
tips. Four fetuses with medial dorsal dark spots were found in the saline
and polysorbate groups (fig. 6). Dissection showed no spinal defects in
'~ny, of these specinlens. Enlarged digits \-Jere found on three specilnens
.
from the saline, ~X~ and 5X groups (fig. 7). In general, none of these
anomalies were related to experimental treatments, but instead represented
random developmental events.
Skeletal examination of the fetuses revealed vertebral variations,
supernunlerary ribs, and malformed ribs. No major deformations of the
limbs, paws, or skull were detected.
Variations in the ve}~tebra occurred in the center portion and were
classified as bilobed or split centra (fig. 8). They \~ere found in several
control and experimental groups. A chi square test for significance was
performed between the three control groups and the five experimental groups .
•
The three control groups were also compared to the 20X plus 5X groups, and
the 20X group. The controls had a significantly lower incidence (.05 level)
of vertebral variations as compared to the experi~2ntal groups. (fig. 9)
Supernunlerary or 14th rudimentary ribs \·:ere also found in several
controls and experimental groups. The rudi~entarj ribs varied from
small ossification centers to partially for~ed ribs (fig. 10). In addition,
they \~ere found as unilateral and bilateral structures. Statistical analysis
revealed a significant increase at the .01 level _for rUdimentary ribs. in the
three experimental groups (1/2X to 2QX, 5X + 20X) and 20X). Deformed ribs
appeared as wavy ribs (fig. 11) and appeared in groups: lX, 2X, and 5X.
However, the incidence was too small for statistical analysis (fig. 12)
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ONE ~!AY ANALYSIS OF Vp.RIA~~CE
FOR VARIABLES ONE TO FIVe
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normal saline polysorbate 1/2X lX 2X 5X 20X ratio probe
X
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sites
%
resorbed 12.3 3.5 9. 1 5.4 19.7 0 11.8 33.3 1.10 .39
%
Male 48 41.8 46 45.3 55.1 46.6 43.3 33.3 1.29 .29
X
# of live 10 11 10 10.6 9.8 11.6 12 8 .955 .48
fetuses
X
total 26.8 25.8 26.7 28.9 26.5 33.7 32.8 21.7 .96 .48
fetal
weight
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figure 3
Deformed rear leg
2X Group
figure 4
No tail tip Polysorbate group
figure 5
Tail tip less than lmm - Normal group
figure 5
Tail tip greater than lmm - 5X group
figure 5
Dark spot on dorsal surface of fetus from polysorbate group
figure 6
Enlarged digits on fetus from group 2X
figure 7
Chi Square test of Control and Treatment Groups
Bilobular and Split Centra
Groups
I Controls - Groups ~X to 20X
II Controls - Groups 5X + 20X
III Controls - Group 20X
Probability
P = .0129
P = .01
P = .02
Rudimentary Ribs
Groups
I Controls = Groups ~X to 20X
II Controls - Groups 5X to 20X
III Controls - Group 20X
figure 9
Probabi 1i.t\!
-----:---
P = .00005
P = .000002
P = .00001
figure 8 Split and bilobular centra .
.figure 10 Bilateral rudimentary 14th rib ..
Deformed ribs
figure 11
SKELETAL VARIATIONS IN OFFSPRlNG OF RATS
Group
%Rudimentary or Extra Ribs
Unilateral - Bilateral Total
%Bi lobu far
or Spl it %Malformed
Centra Ribs
Control
Sal i ne
Polysorbate
1/2X
2.27
5.45
3.57
28.27 •
3.64
10.71
30.43
2.27
9.09
14.29
58.70
6.82
20.
25.
19.57
IX
2X
5X
12.50
18.52
24.44
5. 17.50
3.70 22.22
2.22· 26.67
37.5
38.89
24.44
5.
1.85
4.44
20X 33.33 8.33
figure 12
41.67 20.83
•
Fetuses fro~ groups: Normal, Saline, Polysorbate,
lX, 2X, 5X (upper left to rtght)
figure 13
Fetuses from groups: Normal, Saline, Polysorbate,
lX, 2X, 5X, (upper left to right)
figure 13
Fetuses from groups: Normal, Saline, Polysorbate and ~X
(upper left to right)
figure 14
Fetuses from groups: IX, 2X, 5X and 20X (upper left to right)
figure 15
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DISCUSSION
Recently hormonal pregnancy tests have been implicated as potentially
teratogenic agents. Retrospective studies have associated them with
masculinization of the female fetus, spinal defects, VACTEL syndrome, and
increased spontaneous abortion rate. In response, the F.D.A. in March 1975
\'Ji thdrehl approval of horn-Iona1 pre9nancy tests because of thei r reported
teratogenic potential. This study examined the effect of hormonal pregnancy
tests on the fetuses of albino rats. The study stayed within physiologic
dose limits (1/2X to 20X) with no attempt to study the effect of experime~tal
teratogenic dosages.
In general, the resul ts of the experilnent di d not support the contenti on
that hormonal pregnancy tests are potentially dangerous to rat fetal development.
This study found no increase in the per cent of resorbed fetuses in treatment
groups. This was in contrast to Brotherton and Craft25 and Crombie et a1 26 who
had reported increased spontaneous abortions and still births in humans with the
.
use of pregnancy test agents.
In this experiment, no genital anomalies were found and no increase in
percentage of male fetuses in treatment groups. Masculinization could not be
clearly identified as no dissection of fetuses was performed in the present
study. The present study did not examine for esophageal atresia, anal anomalies,
T.G.V., and tracheal anomalies, as reported by Nora2l , Levy22, and Mitchel1 23 .
Skeletally there were significant increases in bilobular and split vertebra
centra and extra rudimentary ribs in the experimental group. However, the
centra and .ribs may not be anomalies but variations of normal skeletal structures.
It is difficult to speculate how these variations would have expressed themselve~
in fully developed rats. Kuhns and Hormel1 47 reported that scoliosis and ortho-
pedic problems in children are associated with variations and numerical altera-
tions in the vertebra. However, Kimmel and Wilson48 indicated that extra
rudilnentary ribs and bilobular' centra should not be classified as abnorinal
and they may only be a sign of embriotoxicity. Also, Bertilli and Donat;49
stated that the incidence of extra ribs is too high in nornlal rabbits to
be classified as an abnormality; however, it may be an indicator of drug
activity.
In conclusion, this study did not find conclusive evidence that oral
hormonal pregnancy tests at physiological doses are a treatcgenic agent
in white rats.
•
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